Compare Consolidated Edison, Inc. (ED) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Summit Therapeutics Inc — how do they compare? Consolidated Edison, Inc. trades at $106.14 (market cap $39.20B), while Summit Therapeutics Inc trades at $17 (market cap $13.71B). The key difference: Consolidated Edison, Inc. is far larger — about 2.9× Summit Therapeutics Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and Summit Therapeutics Inc for 16 Days on average.
| ED | SMMT | |
|---|---|---|
Market Cap | $39.20B | $13.71B |
Volume | 2,142,900 | 6,173,057 |
Sector | Utilities | Health |
52-Week High | $115.46 | $26.38 |
52-Week Low | $95.37 | $12.43 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $66.05B | $13.04B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The company maintains solid fundamentals with a P/E of 17.43, net income margin of 12.53%, and a $0.89 dividend. Revenue grew to $16.92B in 2025, with cash flow from operations strong at $4.80B. Analyst consensus is a Hold with a $106.33 price target, slightly above the current price.
ED's outlook is stable, supported by its utility business model and dividend aristocrat status, but faces risks from high debt levels and interest expenses. The stock offers income appeal with moderate growth potential, though investor sentiment is cautious amid mixed analyst ratings and institutional selling trends noted in recent filings.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
